Industry Satellite Symposia

This symposium is organised and entirely funded by Vertex Pharmaceuticals.

Due to pharmaceutical industry regulations, this symposium is for healthcare professionals (HCPs) and scientific professionals only, it is not open to patients or members of the public.

Thursday 5 June 2025

13:00–14:00 CEST

Coral 2&3, Level 2,
Allianz MiCo,
Milan, Italy

Expanding CFTR-based treatment for people with CF

	Objectives: Discuss the recent advances in understanding of CFTR science through clinical trials and real-world studies Highlight the relationship between restoration of CFTR function to normal levels and improved clinical outcomes Discuss the continued progress and effort with genetic therapies Chaired by: Prof Jane Davies, Imperial College London, UK Panellists: Prof Isabelle Fajac, AP-HP Université Paris Cité, Paris, France Dr Simon Gräber, Charité-Universitätsmedizin Berlin, Germany Dr Fred Van Goor, Vice President, Cystic Fibrosis Research, Vertex Pharmaceuticals, USA
Time (CEST)	Presentation	Presenter/s
13:00–13:15	Chair’s opening remarks: The CF care journey continues	Prof Jane Davies
13:15–13:30	Review the recent advances in understanding CFTR science	Dr Fred Van Goor
13:30–13:45	Measurements of CFTR function and relationship with clinical outcomes	Prof Isabelle Fajac and Dr Simon Gräber
13:45–13:55	Discuss the continued progress and effort with genetic therapies	Prof Jane Davies
13:55–14:00	Chair’s closing remarks	Prof Jane Davies

Questions and comments from the audience is encouraged throughout the symposium.

CFTR, cystic fibrosis transmembrane conductance regulator; pwCF, people with cystic fibrosis.

Friday 6 June 2025

Coral 2&3, Level 2

Allianz MiCo
Milan, Italy

Digging deeper into DPP1 (CatC) and its role in the shared pathophysiology of non-CF and CF bronchiectasis
Boehringer Ingelheim Breakfast Session at ECFS 2025

	Co-chairs: James Chalmers and Marcus Mall
Time (CEST)	Presentation title	Presenter
08:00-08:03	Welcome and introduction	James Chalmers
08:03-08:23	A case of shared pathophysiology: neutrophilic inflammation and the vicious vortex in non-CF and CF bronchiectasis	James Chalmers
08:23-08:43	Investigating the role of DPP1 (CatC) in CF bronchiectasis	Marcus Mall
08:43-08:45	Final remarks and meeting close	Marcus Mall

This symposium is organised and entirely funded by Vertex Pharmaceuticals.

Due to pharmaceutical industry regulations, this symposium is for healthcare professionals (HCPs) and scientific professionals only, it is not open to patients or members of the public.

Friday 6 June 2025

13:00–14:00 CEST

Coral 2&3, Level 2,
Allianz MiCo,
Milan, Italy

Unmet needs and clinical challenges in the CFTR modulator era

	Objectives: Address the remaining needs in the CF community, focussing on pwCF living longer in the CFTRm era Discuss the emerging clinical needs in pwCF despite on CFTRm (early and late starters on CFTRm), their treatment goals and how these may be overcome through improvement of CFTR function towards normal levels Consider the important role of MDTs in supporting the ageing CF population Chaired by: Prof Francesco Blasi, IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy Speakers: Dr Gwyneth Davies, University College London, London, UK Prof Andrea Gramegna, IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy Dr Sarah Collins, Royal Brompton and Harefield Hospitals, London, UK
Time (CEST)	Presentation	Presenter/s
13:00–13:10	Chair’s opening remarks: What does the future look like for people with CF?	Prof Francesco Blasi
13:10–13:25	Addressing the clinical needs in pwCF who initiate early onto CFTRm	Dr Gwyneth Davies
13:25–13:40	Addressing the clinical needs in pwCF who start late on CFTRm with established disease	Prof Andrea Gramegna
13:40-13:50	Ageing with CF: The supporting role of the MDTs	Dr Sarah Collins
13:50–14:00	Chair’s closing remarks	Prof Francesco Blasi

Questions and comments from the audience is encouraged throughout the symposium.

CFTRm, cystic fibrosis transmembrane conductance regulator modulator; MDT, multidisciplinary team; pwCF, people with cystic fibrosis.

The 48th European Cystic Fibrosis Conference has been assessed as compliant by EthicalMedTech.
Please view the assessment details: click here